24 results on '"Fehres CM"'
Search Results
2. Label-free detection of prostaglandin transporter (SLCO2A1) function and inhibition: insights by wound healing and TRACT assays.
- Author
-
Mocking TAM, van Oostveen WM, van Veldhoven JPD, Minnee H, Fehres CM, Whitehurst CE, IJzerman AP, and Heitman LH
- Abstract
The prostaglandin transporter (PGT, SLCO2A1) mediates transport of prostanoids (a.o. prostaglandin E2 (PGE
2 )) into cells and thereby promotes their degradation. Overexpression of PGT leads to low extracellular PGE2 levels and has been linked to impaired wound healing of diabetic foot ulcers. Inhibition of PGT could thus be beneficial, however, no PGT inhibitors are currently on the market and drug discovery efforts are hampered by lack of high-through screening assays for this transporter. Here we report on a label-free impedance-based assay for PGT that measures transport activity through receptor activation (TRACT) utilizing prostaglandin E2 receptor subtype EP3 and EP4 that are activated by PGE2 . We found that induction of PGT expression on HEK293-JumpIn-SLCO2A1 cells that also express EP3 and EP4 leads to an over 10-fold reduction in agonistic potency of PGE2 . PGE2 potency could be recovered upon inhibition of PGT-mediated PGE2 uptake with PGT inhibitors olmesartan and T26A, the potency of which could be established as well. Moreover, the TRACT assay enabled the assessment of transport function of PGT natural variants. Lastly, HUVEC cells endogenously expressing prostanoid receptors and PGT were exploited to study wound healing properties of PGE2 and T26A in real-time using a novel impedance-based scratch-induced wound healing assay. These novel impedance-based assays will advance PGT drug discovery efforts and pave the way for the development of PGT-based therapies., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Mocking, van Oostveen, van Veldhoven, Minnee, Fehres, Whitehurst, IJzerman and Heitman.)- Published
- 2024
- Full Text
- View/download PDF
3. Anti-carbamylated protein antibodies in systemic sclerosis.
- Author
-
Liem SIE, Hoekstra EM, Levarht EWN, Dorjee AL, Scherer HU, Toes REM, Huizinga TWJ, de Vries-Bouwstra JK, and Fehres CM
- Subjects
- Humans, Female, Male, Immunoglobulin A, Immunoglobulin G, Immunoglobulin M, Antibodies, Antinuclear, Scleroderma, Systemic diagnosis
- Abstract
Background: To investigate the presence of different isotypes of anti-carbamylated protein (CarP) antibodies in systemic sclerosis (SSc) patients and its association with skin involvement., Methods: Sera of 194 SSc patients from the Leiden CCISS cohort, fulfilling ACR/EULAR 2013 criteria and a clinical diagnosis of SSc, 83 patients with other connective tissue diseases/Raynaud's Phenomenon, 24 rheumatoid arthritis patients and 98 age and sex-matched healthy controls were tested for the presence of anti-CarP IgG, IgA and IgM, determined by ELISA. Clinical characteristics, that were evaluated in SSc patients, included age, anti-topoisomerase antibodies (ATA), anti-centromere antibodies (ACA) and modified Rodnan Skin Score (mRSS)., Results: The SSc patients were 55 (SD:13) years and 155 (80%) were female. Forty-four (23%) patients tested positive for ATA, and 80 (42%) ACA. The median mRSS was 2 (range: 0; 47). Prevalence of anti-CarP IgG was higher in SSc patients than in healthy controls (8% vs 3%, p = 0.007. Prevalence of anti-CarP IgA and IgM and levels of anti-CarP isotypes were comparable between SSc patients and healthy controls. Fifteen (8%) SSc patients tested positive for anti-CarP IgG, 16 (8%) for anti-CarP IgA, and 36 (19%) for anti-CarP IgM. There were no significant correlations between age and levels of anti-CarP isotypes. No correlation between anti-CarP IgG levels and mRSS was found (r = 0.141, p = 0.049), nor for anti-CarP IgM and IgA levels. Anti-CarP IgA levels were higher in ATA compared to ACA positive SSc patients (ATA: 616 aU/ml [359; 1103]; ACA: 424 aU/ml [300; 673], p = 0.015)., Conclusion: SSc patients can test positive for Anti-CarP IgG, IgA and IgM. We do not observe a relevant clinical association between anti-CarP antibody response and skin involvement in SSc., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
4. Anti-topoisomerase, but not anti-centromere B cell responses in systemic sclerosis display active, Ig-secreting cells associated with lung fibrosis.
- Author
-
Wortel CM, Liem SI, van Leeuwen NM, Boonstra M, Fehres CM, Stöger L, Huizinga TW, Toes RE, De Vries-Bouwstra J, and Scherer HU
- Subjects
- Humans, Leukocytes, Mononuclear, Autoantibodies, Immunoglobulin G, Immunoglobulin A, Pulmonary Fibrosis complications, Scleroderma, Systemic diagnosis, Lung Diseases, Interstitial etiology
- Abstract
Objectives: Almost all patients with systemic sclerosis (SSc) harbour autoantibodies. Anti-topoisomerase antibodies (ATA) and anti-centromere antibodies (ACA) are most prevalent and associate with distinct clinical phenotypes. B cell responses underlying these phenotypes are ill-defined. To understand how B cell autoreactivity and disease pathology connect, we determined phenotypic and functional characteristics of autoreactive B cells in ATA-positive and ACA-positive patients., Methods: Levels and isotypes of autoantibodies secreted by ex vivo cultured peripheral blood mononuclear cells from patients with ATA-positive (n=22) and ACA-positive (n=20) SSc were determined. Antibody secreting cells (ASCs) were isolated by cell sorting and cultured separately. Correlations were studied between the degree of spontaneous autoantibody production and the presence and degree of interstitial lung disease (ILD)., Results: Circulating B cells secreting either ATA-immunoglobulin G (IgG) or ACA-IgG on stimulation was readily detectable in patients. The ATA response, but not the ACA response, showed additional secretion of autoreactive IgA. ATA-IgG and ATA-IgA were also secreted spontaneously. Additional cell sorting confirmed the presence of ATA-secreting plasmablasts. The degree of spontaneous ATA-secretion was higher in patients with ILD than in those without (p<0.001) and correlated with the degree of pulmonary fibrosis (p<0.001)., Conclusion: In contrast to ACA-positive patients, ATA-positive patients show signs of recent activation of the B cell response that hallmarks this disease. The degree of activation correlates with the presence and severity of ILD, the most deleterious disease manifestation. This could explain differential responsiveness to B cell depleting therapy. The abundant and spontaneous secretion of ATA-IgG and ATA-IgA may point toward a continuously activating trigger., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
5. Progression from suspected to definite systemic sclerosis and the role of anti-topoisomerase I antibodies.
- Author
-
Liem SIE, Neppelenbroek S, Fehres CM, Wevers BA, Toes REM, Allaart CF, Huizinga TWJ, Scherer HU, and De Vries-Bouwstra JK
- Subjects
- Humans, Disease Progression, DNA Topoisomerases, Type I, United States, Autoantibodies, Raynaud Disease diagnosis, Raynaud Disease epidemiology, Scleroderma, Systemic complications
- Abstract
Introduction: Early diagnosis of systemic sclerosis (SSc) is important to start therapeutic interventions timely. Important risk factors for progression to SSc are the SSc-specific autoantibodies, of whom anti-centromere antibodies (ACA) and anti-topoisomerase I antibodies (ATA) are the most frequent. ATA is associated with a severe disease course. A more detailed characterisation of the ATA-response in SSc might increase insights in preclinical disease stages and improve prognostication. To address this we identified all patients with suspected very early ATA-positive SSc, defined as all patients who are ATA-positive not fulfilling American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) 2013 criteria, in the Leiden Combined Care in Systemic Sclerosis (CCISS)-cohort and found very low numbers., Methods: This triggered us to search the literature on the ATA prevalence in patients with suspected very early SSc and contribution of the SSc-specific autoantibodies to progression from suspected very early to definite SSc. To increase insights on the ATA-response in suspected very early SSc, we then evaluated the association between the ATA-response and time between onset of Raynaud's phenomenon (RP) and first non-RP symptom, as a proxy for progressing to definite SSc, in all patients with ATA-positive SSc from the Leiden CCISS-cohort., Results: In short, included studies show that prevalence of ATA is much lower in suspected very early SSc than in populations fulfilling ACR/EULAR 2013 criteria. After 1-15 years of follow-up, only 52% of the patients with suspected very early SSc progress to definite SSc. ATA-IgG levels tend to be higher in patients with ATA-positive SSc with more rapid disease progression., Conclusion: Although a role of ATA in disease progression is suggested, more studies on the ATA response in suspected very early SSc are warranted., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
6. Autoreactive B cell responses targeting nuclear antigens in systemic sclerosis: Implications for disease pathogenesis.
- Author
-
Liem SIE, Neppelenbroek S, Fehres CM, Wortel C, Toes REM, Huizinga TWJ, Scherer HU, and de Vries-Bouwstra JK
- Subjects
- Humans, Antigens, Nuclear, Autoantibodies, Antibodies, Antinuclear, Scleroderma, Systemic diagnosis
- Abstract
A hallmark of disease pathogenesis of systemic sclerosis (SSc) is the presence of autoreactive B cell responses targeting nuclear proteins. Almost all SSc-patients harbour circulating antinuclear autoantibodies of which anti-topoisomerase 1, anti-centromere protein, anti-RNA polymerase III and anti-fibrillarin autoantibodies (ATA, ACA, ARA and AFA, respectively) are the most common and specific for SSc. In clinical practice, autoantibodies serve as diagnostic biomarkers and can aid in the identification of clinical phenotypes of the disease. However, factors driving disease progression in SSc are still poorly understood, and it is difficult to predict disease trajectories in individual patients. Moreover, treatment decisions remain rather empirical, with variable response rates in clinical trials due to patient heterogeneity. Current evidence has indicated that certain patients may benefit from B cell targeting therapies. Hence, it is important to understand the contribution of the antinuclear autoantibodies and their underlying B cell response to the disease pathogenesis of SSc., (Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
7. Anti-C1q autoantibodies may not serve as an adequate biomarker for lung manifestations in systemic sclerosis: a single-centre, cross-sectional study.
- Author
-
Dijkstra DJ, Liem SIE, van Leeuwen NM, Fehres CM, de Vries-Bouwstra JK, and Trouw LA
- Subjects
- Autoantibodies, Biomarkers, Complement C1q, Cross-Sectional Studies, Humans, Lung, Lupus Erythematosus, Systemic, Scleroderma, Systemic complications, Scleroderma, Systemic diagnosis
- Published
- 2021
- Full Text
- View/download PDF
8. Association Between Centromere- and Topoisomerase-specific Immune Responses and the Degree of Microangiopathy in Systemic Sclerosis.
- Author
-
van Leeuwen NM, Wortel CM, Fehres CM, Bakker JA, Scherer HU, Toes REM, Huizinga TWJ, and de Vries-Bouwstra JK
- Subjects
- Autoantibodies, Centromere, Humans, Immunity, Microscopic Angioscopy, Scleroderma, Systemic
- Abstract
Objective: Autoreactive antibody responses, including the use of several isotypes of autoantibodies, have been shown to be associated with clinical outcome in several rheumatic autoimmune diseases. The goals of this study were to evaluate whether (1) anticentromere antibody (ACA)- and antitopoisomerase antibody (ATA)-specific isotype expression, and (2) organ involvement are associated with the degree of microangiopathy in systemic sclerosis (SSc)., Methods: ACA and ATA IgG, IgM, and IgA levels were measured in baseline serum samples of ACA IgG-positive (+) and ATA IgG+ patients with SSc. The degree of microangiopathy was determined based on nailfold videocapillaroscopy (NVC) images collected at the same point in time. Logistic regression analyses with autoantibodies, clinical characteristics, isotype expression, and ACA and ATA IgG, IgM, and IgA levels as independent variables, and NVC pattern as the dependent variable were performed., Results: In 164 patients, isotype levels and degree of microangiopathy were evaluated. Logistic regression confirmed the association of the degree of microangiopathy with the presence of digital ulcers (OR 3.07, 95% CI 1.43-6.60), interstitial lung disease (OR 3.41, 95% CI 1.11-10.61), and pulmonary arterial hypertension (OR 5.58, 95% CI 2.05-17.81). ATA positivity was associated with more severe microangiopathy (OR 2.09, 95% CI 1.05-4.13). Patients who expressed solely ACA IgG showed a trend towards less severe microangiopathy compared to patients also expressing ACA IgM and/or IgA. Levels of ACA IgG and ATA IgM were found to be associated with microangiopathy severity., Conclusion: We observed an association between ACA and ATA responses and the degree of microangiopathy in SSc. These findings might indicate that the breadth of the autoimmune response, as reflected by autoantibody production and microvascular damage, interacts in the pathophysiology of SSc., (Copyright © 2021 by the Journal of Rheumatology.)
- Published
- 2021
- Full Text
- View/download PDF
9. BOB.1 controls memory B-cell fate in the germinal center reaction.
- Author
-
Levels MJ, Fehres CM, van Baarsen LGM, van Uden NOP, Germar K, O'Toole TG, Blijdorp ICJ, Semmelink JF, Doorenspleet ME, Bakker AQ, Krasavin M, Tomilin A, Brouard S, Spits H, Baeten DLP, and Yeremenko NG
- Subjects
- Animals, Biomarkers, Cell Line, Gene Expression, Humans, Lymph Nodes immunology, Lymph Nodes metabolism, Lymph Nodes pathology, Mice, Mice, Knockout, Plasma Cells immunology, Plasma Cells metabolism, Receptors, Antigen, B-Cell metabolism, Rheumatic Fever genetics, Rheumatic Fever immunology, Rheumatic Fever metabolism, Rheumatic Fever pathology, T-Lymphocytes immunology, T-Lymphocytes metabolism, B-Lymphocytes immunology, B-Lymphocytes metabolism, Germinal Center immunology, Germinal Center metabolism, Immunologic Memory genetics, Trans-Activators genetics
- Abstract
During T cell-dependent (TD) germinal center (GC) responses, naïve B cells are instructed to differentiate towards GC B cells (GCBC), high-affinity long-lived plasma cells (LLPC) or memory B cells (Bmem). Alterations in the B cell-fate choice could contribute to immune dysregulation leading to the loss of self-tolerance and the initiation of autoimmune disease. Here we show that mRNA levels of the transcription regulator BOB.1 are increased in the lymph node compartment of patients with rheumatoid arthritis (RA), a prototypical autoimmune disease caused by the loss of immunological tolerance. Investigating to what extent levels of BOB.1 impact B cells during TD immune responses we found that BOB.1 has a crucial role in determining the B cell-fate decision. High BOB.1 levels promote the generation of cells with phenotypic and functional characteristics of Bmem. Mechanistically, overexpression of BOB.1 drives ABF1 and suppresses BCL6, favouring Bmem over LLPC or recycling GCBC. Low levels of BOB.1 are sufficient for LLPC but not for Bmem differentiation. Our findings demonstrate a novel role for BOB.1 in B cells during TD GC responses and suggest that its dysregulation may contribute to the pathogenesis of RA by disturbing the B cell-fate determination., (Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
10. APRIL Induces a Novel Subset of IgA + Regulatory B Cells That Suppress Inflammation via Expression of IL-10 and PD-L1.
- Author
-
Fehres CM, van Uden NO, Yeremenko NG, Fernandez L, Franco Salinas G, van Duivenvoorde LM, Huard B, Morel J, Spits H, Hahne M, and Baeten DLP
- Subjects
- Animals, B7-H1 Antigen genetics, B7-H1 Antigen metabolism, Cells, Cultured, Disease Models, Animal, Gene Expression Regulation, Humans, Immune Tolerance, Immunoglobulin A metabolism, Interleukin-10 genetics, Interleukin-10 metabolism, Mice, Mice, Transgenic, Tumor Necrosis Factor Ligand Superfamily Member 13 genetics, B-Lymphocyte Subsets immunology, B-Lymphocytes, Regulatory immunology, Dermatitis, Contact immunology, Encephalomyelitis, Autoimmune, Experimental immunology, Inflammation immunology, Multiple Sclerosis immunology, Tumor Necrosis Factor Ligand Superfamily Member 13 metabolism
- Abstract
Regulatory B cells (Bregs) are immunosuppressive cells that modulate immune responses through multiple mechanisms. The signals required for the differentiation and activation of these cells remain still poorly understood. We have already shown that overexpression of A PRoliferation-Inducing Ligand (APRIL) reduces the incidence and severity of collagen-induced arthritis (CIA) in mice. Furthermore, we have described that APRIL, but not BAFF, promoted IL-10 production and regulatory functions in human B cells. Therefore, we hypothesized that APRIL, but not BAFF, may be involved in the induction and/or activation of IL-10 producing Bregs that suppress inflammatory responses in vitro and in vivo . Here, we describe that APRIL promotes the differentiation of naïve human B cells to IL-10-producing IgA
+ B cells. These APRIL-induced IgA+ B cells display a Breg phenotype and inhibit T cell and macrophage responses through IL-10 and PD-L1. Moreover, APRIL-induced IL-10 producing Bregs suppress inflammation in vivo in experimental autoimmune encephalitis (EAE) and contact hypersensitivity (CHS) models. Finally, we showed a strong correlation between APRIL and IL-10 in the inflamed synovial tissue of inflammatory arthritis patients. Collectively, these observations indicate the potential relevance of this novel APRIL-induced IgA+ Breg population for immune homeostasis and immunopathology.- Published
- 2019
- Full Text
- View/download PDF
11. Generation and Characterization of Anti-Citrullinated Protein Antibody-Producing B Cell Clones From Rheumatoid Arthritis Patients.
- Author
-
Germar K, Fehres CM, Scherer HU, van Uden N, Pollastro S, Yeremenko N, Hansson M, Kerkman PF, van der Voort EIH, Reed E, Maassen H, Kwakkenbos MJ, Bakker AQ, Klareskog L, Malmström V, de Vries N, Toes REM, Lundberg K, Spits H, and Baeten DL
- Subjects
- Autoantibodies immunology, Clone Cells immunology, Cytokines metabolism, Enzyme-Linked Immunosorbent Assay, Epitopes immunology, Humans, Synovial Fluid immunology, Anti-Citrullinated Protein Antibodies immunology, Arthritis, Rheumatoid immunology, Autoantigens immunology, B-Lymphocytes immunology, Peptides, Cyclic immunology
- Abstract
Objective: Anti-citrullinated protein antibodies (ACPAs) are a hallmark of rheumatoid arthritis (RA). Aside from autoantibody production, the function of autoantigen-specific B cells remains poorly understood in the context of this disease. This study set out to elucidate autoantigen-specific B cell functions through the isolation and immortalization of unique citrullinated protein/peptide (CP)-reactive B cell clones from RA patients., Methods: B cell clones from either the blood or synovial fluid of cyclic citrullinated peptide 2 (CCP2) antibody-positive RA patients were immortalized by genetic reprogramming with Bcl-6 and Bcl-xL. Enzyme-linked immunosorbent assay and flow cytometry were used to identify CCP2-reactive clones and to further characterize surface marker and cytokine expression as well as B cell receptor signaling competence. Global gene expression profiles were interrogated by RNA sequencing., Results: Three unique CP-reactive memory B cell clones were generated from the blood or synovial fluid of 2 RA patients. CP-reactive memory B cells did not appear to be broadly cross-reactive, but rather had a fairly restricted epitope recognition profile. These clones were able to secrete both pro- and antiinflammatory cytokines and had a unique surface profile of costimulatory molecules and receptors, including CD40 and C5a receptor type 1, when compared to non-CP-reactive clones from the same patient. In addition, CP-reactive clones bound citrullinated protein, but not native protein, and could mobilize calcium in response to antigen binding., Conclusion: CP-reactive memory B cells comprise a rare, seemingly oligoclonal population with restricted epitope specificity and distinct phenotypic and molecular characteristics suggestive of antigen-presenting cells. Cloning by genetic reprogramming opens new avenues to study the function of autoreactive memory B cells, especially in terms of antigen processing, presentation, and subsequent T cell polarization., (© 2018, American College of Rheumatology.)
- Published
- 2019
- Full Text
- View/download PDF
12. Anti-citrullinated protein antibody response after primary EBV infection in kidney transplant patients.
- Author
-
Kraal LJN, Nijland ML, Germar KL, Baeten DLP, Ten Berge IJM, and Fehres CM
- Subjects
- Adult, Aged, Epstein-Barr Virus Infections etiology, Female, Glomerulonephritis, IGA blood, Glomerulonephritis, IGA etiology, Humans, Kidney Transplantation, Male, Middle Aged, Anti-Citrullinated Protein Antibodies blood, Epstein-Barr Virus Infections blood, Herpesvirus 4, Human
- Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease of synovial joints, characterized by the presence of the highly disease-specific anti-citrullinated protein antibodies (ACPA) in approximately 70% of patients. Epstein-Barr virus (EBV) has previously been suggested to be involved in the pathophysiology of RA. However, given the high incidence of EBV in the general population and the difficulty of detecting initial infection, providing a direct link between EBV infection and RA development has remained elusive. We hypothesized that primary EBV infection may be a trigger for the development of the ACPA response in vivo. Using a unique cohort of 26 kidney transplant patients with a primary EBV infection, the presence of ACPA before and following infection was determined. No increase in IgG anti-CCP2 titers was detected following EBV infection. IgG anti-CCP2 antibodies were present in two patients and borderline positive in another. These three patients were HLA-DR4 negative. To test whether EBV infection may trigger a non-class switched anti-CCP2 response, IgM anti-CCP2 antibodies were analyzed. No general trend in the IgM anti-CCP2 response was observed following EBV infection. Since two out of the three IgG anti-CCP2 (borderline) positive patients were diagnosed with IgA nephropathy, 23 additional IgA nephropathy patients were tested for IgG anti-CCP2, regardless of their EBV status. All of these patients were IgG anti-CCP2 negative, indicating that IgG anti-CCP2 is not commonly present in IgA nephropathy patients. Collectively, these data do not support the hypothesis that EBV does trigger the highly RA specific ACPA response.
- Published
- 2018
- Full Text
- View/download PDF
13. Langerin-mediated internalization of a modified peptide routes antigens to early endosomes and enhances cross-presentation by human Langerhans cells.
- Author
-
Fehres CM, Duinkerken S, Bruijns SC, Kalay H, van Vliet SJ, Ambrosini M, de Gruijl TD, Unger WW, Garcia-Vallejo JJ, and van Kooyk Y
- Subjects
- Antibodies metabolism, Cell Compartmentation, Cell Differentiation drug effects, Cross-Priming drug effects, Endosomes drug effects, Humans, Langerhans Cells cytology, Langerhans Cells drug effects, Ligands, Poly I-C pharmacology, Skin metabolism, Toll-Like Receptors metabolism, Antigens metabolism, Antigens, CD metabolism, Cross-Priming immunology, Endocytosis drug effects, Endosomes metabolism, Langerhans Cells metabolism, Lectins, C-Type metabolism, Mannose-Binding Lectins metabolism, Peptides metabolism
- Abstract
The potential of the skin immune system to generate immune responses is well established, and the skin is actively exploited as a vaccination site. Human skin contains several antigen-presenting cell subsets with specialized functions. In particular, the capacity to cross-present exogenous antigens to CD8+ T cells is of interest for the design of effective immunotherapies against viruses or cancer. Here, we show that primary human Langerhans cells (LCs) were able to cross-present a synthetic long peptide (SLP) to CD8
+ T cells. In addition, modification of this SLP using antibodies against the receptor langerin, but not dectin-1, further enhanced the cross-presenting capacity of LCs through routing of internalized antigens to less proteolytic early endosome antigen 1+ early endosomes. The potency of LCs to enhance CD8+ T-cell responses could be further increased through activation of LCs with the toll-like receptor 3 ligand polyinosinic:polycytidylic acid (pI:C). Altogether, the data provide evidence that human LCs are able to cross-present antigens after langerin-mediated internalization. Furthermore, the potential for antigen modification to target LCs specifically provides a rationale for generating effective anti-tumor or anti-viral cytotoxic T lymphocyte responses.- Published
- 2017
- Full Text
- View/download PDF
14. New roles for CD14 and IL-β linking inflammatory dendritic cells to IL-17 production in memory CD4 + T cells.
- Author
-
Ilarregui JM, van Beelen AJ, Fehres CM, Bruijns SC, García-Vallejo JJ, and van Kooyk Y
- Subjects
- CD4-Positive T-Lymphocytes drug effects, Cell Movement drug effects, Dendritic Cells drug effects, Humans, Monocytes cytology, Nuclear Receptor Subfamily 1, Group F, Member 3 metabolism, Peptidoglycan pharmacology, Phenotype, Skin pathology, Solubility, Th17 Cells drug effects, Th17 Cells immunology, Up-Regulation drug effects, CD4-Positive T-Lymphocytes immunology, Dendritic Cells metabolism, Immunologic Memory drug effects, Inflammation pathology, Interleukin-17 biosynthesis, Interleukin-1beta metabolism, Lipopolysaccharide Receptors metabolism
- Abstract
Interleukin (IL)-1β has proven to be crucial in the differentiation of human and mouse Th17 cells. Although it has become evident that IL-1β has potent IL-17-inducing effects on CD4
+ T cells directly, it has not yet been explored whether IL-1β can also prime dendritic cells (DCs) for a Th17 instruction program. Here, we show that human immature DCs exposed to IL-1β promote IL-17 production in human memory CD4+ T cells. IL-1β-primed DCs express high levels of CD14 that mediate IL-17 production through direct interaction with T cells. Moreover, culturing human CD4+ CD45RO+ memory T cells with soluble CD14 is sufficient for the upregulation of retinoic acid-related orphan receptor-γ thymus and IL-17 production. In addition, in a human in situ model using tissue-resident skin DCs, upregulation of CD14 expression induced by IL-1β on skin residents DCs promotes IL-17 production in memory T cells; strongly suggesting the in vivo relevance of this mechanism. Our findings uncover new roles for IL-1β and CD14, and may therefore have important consequences for the development of new therapies for Th17-mediated autoimmune diseases and bacterial and fungal pathogenic infections.- Published
- 2016
- Full Text
- View/download PDF
15. Phenotypic and Functional Properties of Human Steady State CD14+ and CD1a+ Antigen Presenting Cells and Epidermal Langerhans Cells.
- Author
-
Fehres CM, Bruijns SC, Sotthewes BN, Kalay H, Schaffer L, Head SR, de Gruijl TD, Garcia-Vallejo JJ, and van Kooyk Y
- Subjects
- Antigen Presentation immunology, Antigen-Presenting Cells immunology, Biomarkers, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes metabolism, Calcitonin Receptor-Like Protein genetics, Calcitonin Receptor-Like Protein metabolism, Cluster Analysis, Cross-Priming immunology, Cytokines genetics, Cytokines metabolism, Dendritic Cells immunology, Dendritic Cells metabolism, Gene Expression, Gene Expression Profiling, Humans, Immunophenotyping, Inflammation Mediators, Langerhans Cells immunology, Ligands, Toll-Like Receptors genetics, Toll-Like Receptors metabolism, Antigen-Presenting Cells metabolism, Antigens, CD1 metabolism, Epidermal Cells, Epidermis physiology, Langerhans Cells metabolism, Lipopolysaccharide Receptors metabolism, Phenotype
- Abstract
Cutaneous antigen presenting cells (APCs) are critical for the induction and regulation of skin immune responses. The human skin contains phenotypically and functionally distinct APCs subsets that are present at two separated locations. While CD1ahigh LCs form a dense network in the epidermis, the CD14+ and CD1a+ APCs reside in the dermal compartment. A better understanding of the biology of human skin APC subsets is necessary for the improvement of vaccine strategies that use the skin as administration route. In particular, progress in the characterization of uptake and activatory receptors will certainly improve APC-targeting strategies in vaccination. Here we performed a detailed analysis of the expression and function of glycan-binding and pattern-recognition receptors in skin APC subsets. The results demonstrate that under steady state conditions human CD1a+ dermal dendritic cells (DCs) were phenotypically most mature as measured by the expression of CD83 and CD86, whereas the CD14+ cells showed a higher expression of the CLRs DC-SIGN, mannose receptor and DCIR and had potent antigen uptake capacity. Furthermore, steady state LCs showed superior antigen cross-presentation as compared to the dermal APC subsets. Our results also demonstrate that the TLR3 ligand polyribosinic-polyribocytidylic acid (pI:C) was the most potent stimulator of cytokine production by both LCs and dDCs. These studies warrant further exploration of human CD1a+ dDCs and LCs as target cells for cancer vaccination to induce anti-tumor immune responses.
- Published
- 2015
- Full Text
- View/download PDF
16. In situ Delivery of Antigen to DC-SIGN(+)CD14(+) Dermal Dendritic Cells Results in Enhanced CD8(+) T-Cell Responses.
- Author
-
Fehres CM, van Beelen AJ, Bruijns SCM, Ambrosini M, Kalay H, Bloois LV, Unger WWJ, Garcia-Vallejo JJ, Storm G, de Gruijl TD, and Kooyk YV
- Subjects
- Analysis of Variance, Cell Movement, Cells, Cultured, Dendritic Cells immunology, Enzyme-Linked Immunosorbent Assay, Humans, Lipopolysaccharide Receptors metabolism, Liposomes immunology, Liposomes metabolism, Polysaccharides immunology, Polysaccharides metabolism, Sampling Studies, Antigen Presentation immunology, CD8-Positive T-Lymphocytes immunology, Cell Adhesion Molecules immunology, Lectins, C-Type immunology, Lipopolysaccharide Receptors immunology, Receptors, Cell Surface immunology
- Abstract
CD14(+) dendritic cells (DCs) present in the dermis of human skin represent a large subset of dermal DCs (dDCs) that are considered macrophage-like cells with poor antigen (cross)-presenting capacity and limited migratory potential to the lymph nodes. CD14(+) dDC highly express DC-specific ICAM-3-grabbing non-integrin (DC-SIGN), a receptor containing potent endocytic capacity, facilitating intracellular routing of antigens to major histocompatibility complex I and II (MHC-I andII) loading compartments for the presentation to antigen-specific CD8(+) and CD4(+) T cells. Here we show using a human skin explant model that the in situ targeting of antigens to DC-SIGN using glycan-modified liposomes enhances the antigen-presenting capacity of CD14(+) dDCs. Intradermal vaccination of liposomes modified with the DC-SIGN-targeting glycan Lewis(X), containing melanoma antigens (MART-1 or Gp100), accumulated in CD14(+) dDCs and resulted in enhanced Gp100- or MART-1-specific CD8(+) T-cell responses. Simultaneous intradermal injection of the cytokines GM-CSF and IL-4 as adjuvant enhanced the migration of the skin DCs and increased the expression of DC-SIGN on the CD14(+) and CD1a(+) dDCs. These data demonstrate that human CD14(+) dDCs exhibit potent cross-presenting capacity when targeted in situ through DC-SIGN.
- Published
- 2015
- Full Text
- View/download PDF
17. Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens.
- Author
-
Fehres CM, Kalay H, Bruijns SC, Musaafir SA, Ambrosini M, van Bloois L, van Vliet SJ, Storm G, Garcia-Vallejo JJ, and van Kooyk Y
- Subjects
- Amino Acid Sequence, Antigen Presentation, Antigens chemistry, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, Cancer Vaccines administration & dosage, Cancer Vaccines immunology, Carbohydrate Sequence, Dendritic Cells immunology, Drug Delivery Systems, Glycoconjugates chemistry, Glycosphingolipids chemistry, Glycosphingolipids immunology, Humans, Langerhans Cells immunology, Liposomes chemistry, Molecular Sequence Data, Peptides chemistry, Peptides immunology, Polysaccharides chemistry, Antigens immunology, Antigens, CD immunology, Cell Adhesion Molecules immunology, Cross-Priming, Glycoconjugates immunology, Lectins, C-Type immunology, Liposomes immunology, Mannose-Binding Lectins immunology, Polysaccharides immunology, Receptors, Cell Surface immunology
- Abstract
Dendritic cells (DCs) and Langerhans cells (LC) are professional antigen presenting cells (APCs) that initiate humoral and cellular immune responses. Targeted delivery of antigen towards DC- or LC-specific receptors enhances vaccine efficacy. In this study, we compared the efficiency of glycan-based antigen targeting to both the human DC-specific C-type lectin receptor (CLR) DC-SIGN and the LC-specific CLR langerin. Since DC-SIGN and langerin are able to recognize the difucosylated oligosaccharide Lewis Y (Le(Y)), we prepared neoglycoconjugates bearing this glycan epitope to allow targeting of both lectins. Le(Y)-modified liposomes, with an approximate diameter of 200nm, were significantly endocytosed by DC-SIGN(+) DCs and mediated efficient antigen presentation to CD4(+) and CD8(+) T cells. Surprisingly, although langerin bound to Le(Y)-modified liposomes, LCs exposed to Le(Y)-modified liposomes could not endocytose liposomes nor mediate antigen presentation to T cells. However, LCs mediated an enhanced cross-presentation when antigen was delivered through langerin using Le(Y)-modified synthetic long peptides. In contrast, Le(Y)-modified synthetic long peptides were recognized by DC-SIGN, but did not trigger antigen internalization nor antigen cross-presentation. These data demonstrate that langerin and DC-SIGN have different size requirements for antigen uptake. Although using glycans remains an interesting option in the design of anti-cancer vaccines targeting multiple CLRs, aspects such as molecule size and conformation need to be taken in consideration., (Copyright © 2015 Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
18. Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming.
- Author
-
Fehres CM, Bruijns SC, van Beelen AJ, Kalay H, Ambrosini M, Hooijberg E, Unger WW, de Gruijl TD, and van Kooyk Y
- Subjects
- Administration, Topical, Aminoquinolines immunology, CD8-Positive T-Lymphocytes drug effects, Cancer Vaccines immunology, Cancer Vaccines pharmacology, Cross-Priming immunology, Cytokines immunology, Dendritic Cells drug effects, Humans, Imidazoles immunology, Imidazoles pharmacology, Imiquimod, Injections, Intradermal, Ligands, MART-1 Antigen immunology, Melanoma immunology, Skin immunology, Toll-Like Receptor 7 agonists, Aminoquinolines administration & dosage, CD8-Positive T-Lymphocytes immunology, Dendritic Cells immunology, Toll-Like Receptor 7 immunology
- Abstract
Toll-like receptor (TLR) ligands are attractive candidate adjuvants for therapeutic cancer vaccines, since TLR signaling stimulates and tunes both humoral and cellular immune responses induced by dendritic cells (DCs). Given that human skin contains a dense network of DCs, which are easily accessible via (intra-)dermal delivery of vaccines, skin is actively explored as an antitumor vaccination site. Here we used a human skin explant model to explore the potential of TLR ligands as adjuvants for DC activation in their complex microenvironment. We show that topical application of Aldara skin cream, 5% of which comprises the TLR7 agonist imiquimod, significantly enhanced DC migration as compared with that resulting from intradermal injection of the TLR7/8 ligand R848 or the soluble form of imiquimod. Moreover, Aldara-treated DCs showed highest levels of the costimulatory molecules CD86, CD83, CD40, and CD70. Topical Aldara induced the highest production of pro-inflammatory cytokines in skin biopsies. When combined with intradermal peptide vaccination, Aldara-stimulated DCs showed enhanced cross-presentation of the melanoma antigen MART-1, which resulted in increased priming and activation of MART-1-specific CD8(+) T cells. These results point to advantageous effects of combining the topical application of Aldara with antitumor peptide vaccination., (© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)
- Published
- 2014
- Full Text
- View/download PDF
19. Understanding the biology of antigen cross-presentation for the design of vaccines against cancer.
- Author
-
Fehres CM, Unger WW, Garcia-Vallejo JJ, and van Kooyk Y
- Abstract
Antigen cross-presentation, the process in which exogenous antigens are presented on MHC class I molecules, is crucial for the generation of effector CD8(+) T cell responses. Although multiple cell types are being described to be able to cross-present antigens, in vivo this task is mainly carried out by certain subsets of dendritic cells (DCs). Aspects such as the internalization route, the pathway of endocytic trafficking, and the simultaneous activation through pattern-recognition receptors have a determining influence in how antigens are handled for cross-presentation by DCs. In this review, we will summarize new insights in factors that affect antigen cross-presentation of human DC subsets, and we will discuss the possibilities to exploit antigen cross-presentation for immunotherapy against cancer.
- Published
- 2014
- Full Text
- View/download PDF
20. Effects of antigen-expressing immunostimulatory liposomes on chemotaxis and maturation of dendritic cells in vitro and in human skin explants.
- Author
-
Lanzi A, Fehres CM, de Gruijl TD, van Kooyk Y, and Mastrobattista E
- Subjects
- Animals, Antigens genetics, Cell Line, Chemistry, Pharmaceutical methods, Chemotaxis genetics, Dendritic Cells metabolism, Drug Delivery Systems methods, Humans, Immunization, Liposomes metabolism, Mice, Monocytes immunology, Monocytes metabolism, Skin metabolism, Up-Regulation genetics, Up-Regulation immunology, beta-Galactosidase genetics, beta-Galactosidase immunology, Antigens immunology, Chemotaxis immunology, Dendritic Cells immunology, Liposomes immunology, Skin immunology
- Abstract
Purpose: Antigen-Expressing Immunostimulatory Liposomes (AnExILs) represent a novel DNA vaccination platform based on the production of protein antigens from DNA templates inside liposomes mediated by an in vitro transcription and translation (IVTT) mix. The aim of this study was to analyze the effects of AnExILs on different dendritic cells (DCs) models and to better understand the role of the different components of this formulation on its adjuvanticity., Methods: The effect of β-galactosidase-expressing AnExILs on maturation and particle uptake by murine DC cell line, fresh human monocyte-derived DCs or human dermal DCs in skin explants was investigated and compared to the effects of either plain liposomes or IVTT mix alone., Results: AnExILs induced efficient DC chemotaxis and promoted up-regulation of maturation markers on murine DCs, due to the presence of IVTT in the formulation. Furthermore, the amount of active βGal associated with DCs was higher for AnExILs than for free βGal expressed in IVTT or βGal encapsulated into non-adjuvanted liposomes. Most interestingly, the same trend was observed with human DCs., Conclusions: Both IVTT mix and liposomal vehicles were shown to be key components of the AnExIL formulation responsible for its adjuvanticity. AnExILs combine antigen production, adjuvanticity and delivery in one system, and can efficiently activate both murine and human DCs.
- Published
- 2014
- Full Text
- View/download PDF
21. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation.
- Author
-
van Kooyk Y, Unger WW, Fehres CM, Kalay H, and García-Vallejo JJ
- Subjects
- Animals, CD8-Positive T-Lymphocytes immunology, Dendritic Cells immunology, Humans, Mice, Receptors, Pattern Recognition immunology, Vaccines immunology, Antigen Presentation, Cell Adhesion Molecules immunology, Cross-Priming, Lectins, C-Type immunology, Polysaccharides immunology, Receptors, Cell Surface immunology
- Abstract
Dendritic cells are the most efficient professional antigen-presenting cells in pathogen recognition and play a pivotal role in the control of the immune response. Pathogen recognition is ensured by the expression of a vast variety of pattern-recognition receptors. Amongst them are C-type lectins, a large family of receptors characterized by a domain that - in many cases - mediates calcium-dependent glycan binding. C-type lectins facilitate antigen uptake for efficient processing and presentation and, in some cases, also trigger signaling to modulate T cell responses. These properties make C-type lectin receptors ideal candidates for the targeting of antigens to dendritic cells for vaccination. DC-SIGN is a paradigmatic example of C-type lectin receptors on dendritic cells that facilitate vaccination strategies. DC-SIGN is highly expressed on immature conventional dendritic cells, particularly at the mucosa and the dermis, where DCs first encounter pathogens, but also can easily be accessed for vaccination. Upon ligand binding, DC-SIGN rapidly internalizes and directs its cargo into the endo-lysosomal pathway, which results in MHC-II presentation. But antigens targeted to DC-SIGN are also presented efficiently to CD8(+) T cells, suggesting there is an additional endocytic route that leads to cross-presentation. Simultaneous triggering of DC-SIGN and TLRs results in the modulation of cytokine responses and facilitates cross-presentation to enhance CD4(+) and CD8(+) T cell responses. Because the glycan specificity of DC-SIGN has been characterized in detail, glycans can be used for the targeting of antigens to DCs in a DC-SIGN-dependent manner. Glycans represent a great advantage over monoclonal antibodies, they diminish the risk of side effects, are very small, and their production can rely entirely in organic chemistry approaches. Here, we discuss the capacity of glycan-based vaccines to enhance antigen-specific CD4(+) and CD8(+) T cell responses in human skin and mouse model systems., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
22. Skin-resident antigen-presenting cells: instruction manual for vaccine development.
- Author
-
Fehres CM, Garcia-Vallejo JJ, Unger WW, and van Kooyk Y
- Abstract
The induction of antigen-specific effector T cells is driven by proper antigen presentation and co-stimulation by dendritic cells (DCs). For this reason strategies have been developed to instruct DCs for the induction of CD4(+) and CD8(+) T cell responses. Since DCs are localized, amongst other locations, in peripheral tissues such as the skin, new vaccines are aiming at targeting antigens to DCs in situ. Optimal skin-DC targeting in combination with adequate adjuvant delivery facilitates DC maturation and migration to draining lymph nodes and enhances antigen cross-presentation and T cell priming. In this review we describe what DC subsets populate the human skin, as well as current vaccination strategies based on targeting strategies and alternative administration for the induction of robust long-lived anti-cancer effector T cells.
- Published
- 2013
- Full Text
- View/download PDF
23. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells.
- Author
-
Unger WW, van Beelen AJ, Bruijns SC, Joshi M, Fehres CM, van Bloois L, Verstege MI, Ambrosini M, Kalay H, Nazmi K, Bolscher JG, Hooijberg E, de Gruijl TD, Storm G, and van Kooyk Y
- Subjects
- Animals, Antigen Presentation immunology, Antigens, Neoplasm immunology, Cell Adhesion Molecules genetics, Dendritic Cells metabolism, Drug Delivery Systems, Humans, Lectins, C-Type genetics, Liposomes, Mice, Mice, Inbred C57BL, Mice, Transgenic, Polysaccharides administration & dosage, Receptors, Cell Surface genetics, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, Cell Adhesion Molecules immunology, Dendritic Cells immunology, Lectins, C-Type immunology, Polysaccharides immunology, Receptors, Cell Surface immunology
- Abstract
Cancer immunotherapy requires potent tumor-specific CD8(+) and CD4(+) T-cell responses, initiated by dendritic cells (DCs). Tumor antigens can be specifically targeted to DCs in vivo by exploiting their expression of C-type lectin receptors (CLR), which bind carbohydrate structures on antigens, resulting in internalization and antigen presentation to T-cells. We explored the potential of glycan-modified liposomes to target antigens to DCs to boost murine and human T-cell responses. Since DC-SIGN is a CLR expressed on DCs, liposomes were modified with DC-SIGN-binding glycans Lewis (Le)(B) or Le(X). Glycan modification of liposomes resulted in increased binding and internalization by BMDCs expressing human DC-SIGN. In the presence of LPS, this led to 100-fold more efficient presentation of the encapsulated antigens to CD4(+) and CD8(+) T-cells compared to unmodified liposomes or soluble antigen. Similarly, incubation of human moDC with melanoma antigen MART-1-encapsulated liposomes coated with Le(X) in the presence of LPS led to enhanced antigen-presentation to MART-1-specific CD8(+) T-cell clones. Moreover, this formulation drove primary CD8(+) T-cells to differentiate into high numbers of tetramer-specific, IFN-γ-producing effector T-cells. Together, our data demonstrate the potency of a glycoliposome-based vaccine targeting DC-SIGN for CD4(+) and CD8(+) effector T-cell activation. This approach may offer improved options for treatment of cancer patients and opens the way to in situ DC-targeted vaccination., (Copyright © 2012 Elsevier B.V. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
24. Cross-talk between tumor and myeloid cells: how to tip the balance in favor of antitumor immunity.
- Author
-
Lindenberg JJ, Fehres CM, van Cruijsen H, Oosterhoff D, and de Gruijl TD
- Subjects
- Animals, Cell Differentiation, Dendritic Cells immunology, Humans, Mice, Myeloid Cells immunology, Cell Communication, Immunity, Cellular immunology, Immunosuppression Therapy, Myeloid Cells cytology, Neoplasms immunology
- Abstract
Myeloid differentiation is often disturbed in cancer, leading to reduced frequencies of immunostimulatory dendritic cells and an over-representation of immunosuppressive immature myeloid cells, granulocytes and macrophages. As a result of this skewed myeloid differentiation, a highly immunosuppressive myeloid subset becomes prevalent during cancer development; these myeloid-derived suppressor cells are also recruited as a collateral to certain protumorigenic inflammatory processes, resulting in an effective downregulation of T-cell-mediated immune surveillance and antitumor immunity. In this article, some of the important myeloid cell subsets and mediators involved in cancer-related immune suppression are reviewed. Furthermore, cross-talk between tumors and the myeloid compartment, and ways in which it can suppress effective cell-mediated immunity, are discussed, as well as possible therapeutic approaches to tip the balance in favor of antitumor immunity.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.